Document is current
Any future updates will be listed below
-
Authors
Wang, Lishi https://orcid.org/0009-0002-9416-7647
Yang, Guozi
Lei, Hang
Zhang, Yuancheng
Li, Bin
Liu, Miaomiao
Huang, Yushan
Chen, Xiao
Tai, Panpan
Pan, Zhenyu https://orcid.org/0000-0003-0780-7758
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06462222 at ClinicalTrials.govnct06809530 at ClinicalTrials.govDocuments that mention this clinical trial
CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis
https://doi.org/10.1136/jitc-2025-013588
nct06809517 at ClinicalTrials.govDocuments that mention this clinical trial
CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis
https://doi.org/10.1136/jitc-2025-013588
nct06762080 at ClinicalTrials.govDocuments that mention this clinical trial
CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis
https://doi.org/10.1136/jitc-2025-013588
nct06462222 at ClinicalTrials.govDocuments that mention this clinical trial
CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis
https://doi.org/10.1136/jitc-2025-013588
nct06809530 at ClinicalTrials.govDocuments that mention this clinical trial
CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis
https://doi.org/10.1136/jitc-2025-013588
nct06809517 at ClinicalTrials.govDocuments that mention this clinical trial
CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis
https://doi.org/10.1136/jitc-2025-013588
nct06762080 at ClinicalTrials.govDocuments that mention this clinical trial
CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis
https://doi.org/10.1136/jitc-2025-013588
Documents that mention this clinical trial
CSF proteomics identifies ADGRG1 as a predictive biomarker of intrathecal immune checkpoint inhibitor response in leptomeningeal metastasis
https://doi.org/10.1136/jitc-2025-013588
-
Funding
Funding for this research was provided by:
Huizhou Science and Technology Innovation Team Project (2023EQ050012)
Huizhou Outstanding Young Scientific and Technological Talents Program (2025EQ050018)
Guangzhou Medical University Research Ability Enhancement Project (2024SRP215)
Guangdong Basic and Applied Basic Research Foundation (2023A1515140145)
- License Information
